Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

International Trade Center reported for 6 months of 2023 by IFRS

8/28/23 WTCM

Kazanorgsintez to resume construction of a combined cycle power plant

8/28/23 KZOS

INARCTICA started supplying salmon carcasses to Azbuka Vkusa

8/28/23 AQUA

RESK reported for 6 months of 2023 by IFRS

8/28/23 RZSB

Rosseti North Caucasus reported 6 months of 2023 by IFRS

8/28/23 MRKK

Gazprom Neft will launch a hydroisodeparaffinization complex in 2023

8/28/23 SIBN

Severstal started production of cryogenic valves for first time in Russia

8/28/23 CHMF

Acron reported for 6 months 2023 by IFRS

8/28/23 AKRN

Lenta increased sales thanks to Zoomarkets

8/28/23 LENT

VK will get more than 90% in Tetrica's education platform

8/28/23 VKCO